Puma Biotechnology, Inc.( NASDAQ:PBYI ) just released its latest quarterly results and things are looking bullish. Revenues and losses per share were both better than expected, with revenues of US$45m leading estimates by 6.7%. Statutory losses were smaller than the analystexpected, coming in at US$0.07 per share. Earnings are an important time for investors, as they can track a company's performance, look at what the analyst is forecasting for next year, and see if there's been a change in sentiment towards the company. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analyst has changed their mind on Puma Biotechnology after the latest results.
Following the recent earnings report, the consensus from one analyst covering Puma Biotechnology is for revenues of US$222.0m in 2026. This implies a measurable 2.3% decline in revenue compared to the last 12 months. Statutory earnings per share are forecast to nosedive 39% to US$0.29 in the same period. In the lead-up to this report, the analyst had been modelling revenues of US$218.0m and earnings per share (EPS) of US$0.32 in 2026. The analyst seem to have become more bearish following the latest results. While there were no changes to revenue forecasts, there was a substantial drop in EPS estimates.
Check out our latest analysis for Puma Biotechnology
Despite cutting their earnings forecasts,the analyst has lifted their price target 7.1% to US$5.00, suggesting that these impacts are not expected to weigh on the stock's value in the long term.
Of course, another way to look at these forecasts is to place them into context against the industry itself. Over the past five years, revenues have declined around 1.6% annually. Worse, forecasts are essentially predicting the decline to accelerate, with the estimate for an annualised 3.0% decline in revenue until the end of 2026. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenue grow 22% per year. So while a broad number of companies are forecast to grow, unfortunately Puma Biotechnology is expected to see its revenue affected worse than other companies in the industry.
The Bottom Line
The biggest concern is that the analyst reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Puma Biotechnology. Fortunately, the analyst also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that Puma Biotechnology's revenue is expected to perform worse than the wider industry. We note an upgrade to the price target, suggesting that the analyst believes the intrinsic value of the business is likely to improve over time.
With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At least one analyst has provided forecasts out to 2028, which can be seen for free on our platform here.
Don't forget that there may still be risks. For instance, we've identified 2 warning signs for Puma Biotechnology (1 can't be ignored) you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch
with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature.
We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.
It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
